LUKAS BIOMEDICAL INC.

Lukas Biomedical boasts a great team of professional medical experts and biomedical researchers, dedicated to developing high-quality, high-efficiency cellular therapy technologies to help cancer patients regain their health and hope.
Unlike typical biotech companies, Lukas Biomedical utilizes memory T cells with immune memory and specificity. Through patented cell culture technology, we purify and activate the body's immune cells, enabling them to actively identify and attack cancer cells. After being cultured using biotechnology, the patient's own immune cells can not only recognize and attack cancer cells but also survive in the body for over a year, with fewer side effects and lower drug resistance. This helps cancer patients maintain their quality of life during treatment while reducing the risk of recurrence.

Lumieye Technology Co., Ltd.

With over 15 years of expertise in precision mold development, mechanical module design, and end-to-end manufacturing services, Lumieye Technology delivers high-stability and high-efficiency product solutions for global clients.
At Healthcare+ Expo 2025, we will showcase a wide range of plastic components for non-invasive medical devices, including housings and internal parts for ear thermometers, body thermometers, blood pressure monitors, oximeters, glucose meters, disinfectant sprayers, respiratory masks, rehabilitation devices, and beauty devices. In addition to external housings, we specialize in precision internal components and optical design integration, delivering complete and customized system solutions.
Certified under ISO 13485, we specialize in end-to-end support—from mold flow analysis, process optimization, supply chain quality management, and injection molding and assembly—helping our partners accelerate product development while ensuring high consistency and compliance with medical-grade standards.

LumiSTAR Biotechnology, Inc.

LumisTAR partners with leading companies worldwide to deliver end-to-end iPSC automation solutions and pioneer next-generation cell therapies. Our innovations in iPSC technology aim to transform treatment for neurodegenerative diseases, CKD, and cancer.

Other than cell therapy, LumiSTAR also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs. The platform uses iPSC to create disease models for drug discovery and screening, allowing for more accurate and efficient identification of potential drug candidates. LumiSTAR’s drug screening platform can apply on phenotypic screening, drug discovery, toxicity testing, and precision/personalized medicine.